PL2496228T3 - Sposoby leczenia zespołu nadpobudliwości psychoruchowej/deficytu uwagi - Google Patents

Sposoby leczenia zespołu nadpobudliwości psychoruchowej/deficytu uwagi

Info

Publication number
PL2496228T3
PL2496228T3 PL10828500T PL10828500T PL2496228T3 PL 2496228 T3 PL2496228 T3 PL 2496228T3 PL 10828500 T PL10828500 T PL 10828500T PL 10828500 T PL10828500 T PL 10828500T PL 2496228 T3 PL2496228 T3 PL 2496228T3
Authority
PL
Poland
Prior art keywords
deficit
methods
hyperactivity disorder
treating attention
attention
Prior art date
Application number
PL10828500T
Other languages
English (en)
Inventor
Sung James Lee
Susan Marie Melnick
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of PL2496228T3 publication Critical patent/PL2496228T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL10828500T 2009-11-06 2010-11-03 Sposoby leczenia zespołu nadpobudliwości psychoruchowej/deficytu uwagi PL2496228T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25878009P 2009-11-06 2009-11-06
EP10828500.8A EP2496228B1 (en) 2009-11-06 2010-11-03 Methods for treating attention-deficit/hyperactivity disorder
PCT/KR2010/007698 WO2011055965A2 (en) 2009-11-06 2010-11-03 Methods for treating attention-deficit/hyperactivity disorder

Publications (1)

Publication Number Publication Date
PL2496228T3 true PL2496228T3 (pl) 2014-06-30

Family

ID=43970530

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10828500T PL2496228T3 (pl) 2009-11-06 2010-11-03 Sposoby leczenia zespołu nadpobudliwości psychoruchowej/deficytu uwagi

Country Status (13)

Country Link
US (8) US8895609B2 (pl)
EP (1) EP2496228B1 (pl)
JP (1) JP5836280B2 (pl)
KR (1) KR101783632B1 (pl)
CN (1) CN102762201B (pl)
AU (1) AU2010316106B2 (pl)
BR (1) BR112012010670A2 (pl)
CA (1) CA2779457C (pl)
ES (1) ES2447295T3 (pl)
MX (1) MX2012005258A (pl)
PL (1) PL2496228T3 (pl)
RU (1) RU2556585C2 (pl)
WO (1) WO2011055965A2 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2435403T3 (es) 2005-06-08 2013-12-19 Sk Biopharmaceuticals Co., Ltd. Tratamiento de trastornos del sueño y vigilia
KR102173587B1 (ko) 2009-06-22 2020-11-04 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법
US8895609B2 (en) 2009-11-06 2014-11-25 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
MX350745B (es) 2009-11-06 2017-09-14 Sk Biopharmaceuticals Co Ltd * El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US9359290B2 (en) 2013-03-13 2016-06-07 Jazz Pharmaceuticals International Iii Limited Treatment of cataplexy
CN110638805A (zh) * 2013-07-12 2020-01-03 爵士制药国际Iii有限公司 促进吸烟停止
KR102309836B1 (ko) 2013-07-18 2021-10-12 에스케이바이오팜 주식회사 비만의 치료
TWI698415B (zh) * 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
JP6466792B2 (ja) * 2015-07-03 2019-02-06 エスケー バイオファーマスティカルズ カンパニー リミテッド 注意欠陥／多動性障害（ａｄｈｄ）の治療方法
ES2970887T3 (es) 2016-09-06 2024-05-31 Axsome Malta Ltd Forma de solvato de carbamato de (R)-2-amino-3-fenilpropilo
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
EP4316592A3 (en) 2016-10-06 2024-05-01 Axsome Malta Ltd. Carbamoyl phenylalaninol compounds and uses thereof
AU2018278332B2 (en) 2017-06-02 2022-05-19 Jazz Pharmaceuticals Ireland Limited Methods and compositions for treating excessive sleepiness
KR102643275B1 (ko) 2017-07-31 2024-03-04 재즈 파마슈티칼즈 아일랜드 리미티드 카바모일 페닐알라니놀 유사체 및 이의 용도
CN109464151B (zh) * 2018-12-29 2021-09-07 中国科学院深圳先进技术研究院 注意抑制能力获取方法、装置、设备及存储介质
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
JP2024522632A (ja) * 2021-06-11 2024-06-21 エスケー バイオファーマスティカルズ カンパニー リミテッド 自閉症スペクトラム障害（ａｓｄ）を治療する方法
KR20260021022A (ko) * 2023-06-16 2026-02-12 액섬 테라퓨틱스, 인크. 특정 신경계 상태의 치료를 위한 솔리암페톨
KR20260033050A (ko) 2023-06-29 2026-03-10 액섬 테라퓨틱스, 인크. 수유 여성에게 솔리암페톨을 투여하는 방법
WO2025092882A1 (en) * 2023-11-03 2025-05-08 Ignis Therapeutics (Suzhou) Limited COMBINATION OF A NORADRENERGIC α2A RECEPTOR AGONIST AND A NOREPINEPHRINE DOPAMINE REUPTAKE INHIBITOR AND USE THEREOF
WO2025165760A1 (en) * 2024-01-29 2025-08-07 Axsome Therapeutics, Inc. Phenylalkylamino carbamates for use in the treatment of attention deficit/hyperactivity disorder

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5836280B2 (ja) 1976-11-08 1983-08-08 日本鋼管株式会社 焼結排ガス処理用熱交換器の水処理方法
NZ260667A (en) 1993-06-10 1997-05-26 Lilly Co Eli Preventing emesis or treating sexual dysfunction using tetrahydrobenz[cd]indole 6-carboxamides
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
US5756817C1 (en) * 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
IT1275903B1 (it) 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
KR0173863B1 (ko) * 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
EP0873308B1 (en) 1996-10-10 2002-01-02 SK Corporation O-carbamoyl-phenylalaninol compounds and their pharmaceutically useful salts
WO1998017636A1 (en) 1996-10-22 1998-04-30 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
TW402591B (en) 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
AU1282099A (en) * 1997-10-29 1999-05-17 Bonnie M. Davis Method for treatment of disorders of attention
WO1999055674A1 (en) 1998-04-28 1999-11-04 Dainippon Pharmaceutical Co., Ltd. 1-[(1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
US20010029262A1 (en) 1998-06-29 2001-10-11 Sethi Kapil Dev Method of treatment or prophylaxis
TW518218B (en) 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
US20010034320A1 (en) 2000-01-18 2001-10-25 Hans-Michael Brecht NK1-receptor antagonists for treating restless legs syndrome
WO2002050071A1 (en) 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
CN1262272C (zh) 2001-02-27 2006-07-05 奥索-麦克尼尔药品公司 用于预防或治疗运动障碍的氨基甲酸酯化合物
WO2002067922A1 (en) 2001-02-27 2002-09-06 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in the treatment of pain
CA2443108A1 (en) 2001-04-03 2002-10-17 Merck & Co. Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
JP2004537526A (ja) 2001-06-12 2004-12-16 メルク　エンド　カムパニー　インコーポレーテッド 片頭痛の治療又は予防用ｎｒ２ｂ受容体拮抗薬
US7189757B2 (en) * 2001-10-16 2007-03-13 Hypnion, Inc. Treatment of sleep disorders using CNS target modulators
US20040115263A1 (en) 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
JP2006502180A (ja) 2002-09-20 2006-01-19 ファイザー株式会社 ５−ｈｔ４レセプターモジュレーターとしてのｎ−置換されたピペリジニル−イミダゾピリジン化合物
BRPI0409592A (pt) 2003-04-21 2006-05-02 Pfizer compostos imidazopiridina tendo atividade agonìstica do receptor 5-ht4 e atividade antagonìstica do receptor 5-ht3
UA86204C2 (uk) 2003-09-03 2009-04-10 Пфайзер Инк. Сполуки бензімідазолону, які мають 5-нт4 рецепторну агоністичну активність
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
EP1708790B1 (en) 2003-12-02 2010-04-21 PharmaNeuroBoost N.V. Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders
JP4571645B2 (ja) 2003-12-02 2010-10-27 ファルマニューロブースト エン．フェー． Ｄ４および５−ｈｔ２ａアンタゴニスト、逆アゴニストまたは部分アゴニストの使用
EP1548011A1 (en) 2003-12-23 2005-06-29 Neuro3D Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof
WO2005092882A1 (en) 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
JP4874526B2 (ja) 2004-03-25 2012-02-15 株式会社東芝 磁気記録媒体及び磁気記録媒体の製造法、並びに磁気記録再生装置
CA2587481A1 (en) 2004-10-28 2006-05-11 Sk Corporation Phenylalkylamino carbamates adjunctive therapy for depression
GEP20105053B (en) 2005-04-08 2010-07-26 Pfizer Prod Inc Bicyclic [3.1.0] heteroaryl amides as type i glycine transport inhibitors
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
ES2435403T3 (es) * 2005-06-08 2013-12-19 Sk Biopharmaceuticals Co., Ltd. Tratamiento de trastornos del sueño y vigilia
ES2344469T3 (es) 2005-06-22 2010-08-27 Sk Holdings Co., Ltd. Tratamiento de disfuncion sexual.
ZA200711123B (en) * 2005-06-27 2009-08-26 Biovail Lab Int Srl Modified-release formulations of a bupropion salt
AU2005335241B9 (en) 2005-07-26 2012-12-20 Sk Biopharmaceuticals Co., Ltd. Methods for treating substance-related disorders
EP1754476A1 (en) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20080031932A1 (en) * 2006-08-04 2008-02-07 Watson Laboratories, Inc. Transdermal atomoxetine formulations and associated methods
CA2673487A1 (en) 2006-10-13 2008-04-24 Janssen Pharmaceutica Nv Phenylalkylamino carbamate compositions
JP2010506941A (ja) * 2006-10-17 2010-03-04 リセラ，インク． 甲状腺眼症の治療のための方法、組成物及び製剤
HUP0700353A2 (en) * 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
KR102173587B1 (ko) 2009-06-22 2020-11-04 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
MX350745B (es) 2009-11-06 2017-09-14 Sk Biopharmaceuticals Co Ltd * El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
US8895609B2 (en) 2009-11-06 2014-11-25 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome

Also Published As

Publication number Publication date
US11524935B2 (en) 2022-12-13
KR20120080656A (ko) 2012-07-17
US10202335B2 (en) 2019-02-12
US20210070694A1 (en) 2021-03-11
US8895609B2 (en) 2014-11-25
US20190194125A1 (en) 2019-06-27
MX2012005258A (es) 2012-06-19
EP2496228A2 (en) 2012-09-12
RU2556585C2 (ru) 2015-07-10
WO2011055965A3 (en) 2011-10-20
CA2779457A1 (en) 2011-05-12
US20170355668A1 (en) 2017-12-14
CN102762201B (zh) 2013-12-18
JP2013527127A (ja) 2013-06-27
EP2496228B1 (en) 2014-01-15
HK1178060A1 (en) 2013-09-06
ES2447295T3 (es) 2014-03-11
US9663455B2 (en) 2017-05-30
CN102762201A (zh) 2012-10-31
US20150025137A1 (en) 2015-01-22
JP5836280B2 (ja) 2015-12-24
US20120245226A1 (en) 2012-09-27
KR101783632B1 (ko) 2017-10-10
WO2011055965A2 (en) 2011-05-12
US20240376045A1 (en) 2024-11-14
BR112012010670A2 (pt) 2016-04-12
RU2012123155A (ru) 2013-12-20
AU2010316106B2 (en) 2015-10-22
CA2779457C (en) 2017-10-17
AU2010316106A1 (en) 2012-05-24
US20230278950A1 (en) 2023-09-07
EP2496228A4 (en) 2013-04-10
US20260055054A1 (en) 2026-02-26

Similar Documents

Publication Publication Date Title
PL2496228T3 (pl) Sposoby leczenia zespołu nadpobudliwości psychoruchowej/deficytu uwagi
IL257418A (en) Methods for treating addiction
PT2248083T (pt) Método de autenticação
SG11201406192VA (en) Method for assessing the treatment of attention-deficit/hyperactivity disorder
IL209895A0 (en) Compounds for treating beta-amyloidoses
SI2174717T1 (sl) Postopek drobljenja
SMT202000232T1 (it) Metodi per trattare dlbcl
EP2349480A4 (en) SEQUENTIAL OPTIMIZATIONS FOR TREATMENT PLANNING
HUE045548T2 (hu) Rák kezelésére hasznos gyógyszer
IL233017B (en) Methods for treating spinal cord pathologies
PT2096102E (pt) Processo para a produção de metileno-difenil-diisocianatos
EP2282826A4 (en) PROCESS FOR TREATMENT OF ODOR
IL208069A0 (en) Methods for treating psoriasis
PL2526141T3 (pl) Sposób obróbki powierzchniowej
IL218633A0 (en) Methods for treating psoriasis
PL2301893T3 (pl) Sposób oczyszczania ścieku
IL199739A0 (en) Methods for treating psoriasis
EP2453896A4 (en) PROCESS FOR TREATING SCHIZOPHRENIA
EP2331097A4 (en) METHOD FOR TREATING CNS DISEASES
EG26972A (en) Method for treating waste
PL2516716T3 (pl) Sposób obróbki prania
IL232897B (en) Pacetopran for the treatment of attention, concentration and hyperactivity disorder
GB2483039B (en) Method for treating hydrocarbons
GB0912227D0 (en) Compounds for treating proliferative disorders
GB0912376D0 (en) Compounds for treating proliferative disorders